Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
eLife · 2024
DOI: 10.7554/elife.95488 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Raji E Joseph und 7 weiteren Autor:innen. Beteiligte Einrichtung: Roy J. Carver Department of Biochemistry, Biophysics and Molecular Biology, Iowa State University, Ames, United States. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Leukemia, Lymphocytic, Chronic, B-Cell, Protein Kinase Inhibitors, Piperidines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Experimental Cancer Medicine Centre.
Abstract (Originalsprache)
Inhibition of Bruton’s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders, and multiple sclerosis. Since the approval of the first BTK inhibitor (BTKi), Ibrutinib, several other inhibitors including Acalabrutinib, Zanubrutinib, Tirabrutinib, and Pirtobrutinib have been clinically approved. All are covalent active site inhibitors, with the exception of the reversible active site inhibitor Pirtobrutinib. The large number of available inhibitors for the BTK target creates challenges in choosing the most appropriate BTKi for treatment. Side-by-side comparisons in CLL have shown that different inhibitors may differ in their treatment efficacy. Moreover, the nature of the resistance mutations that arise in patients appears to depend on the specific BTKi administered. We have previously shown that Ibrutinib binding to the kinase active site causes unanticipated long-range effects on the global conformation of BTK (Joseph et al., 2020). Here, we show that binding of each of the five approved BTKi to the kinase active site brings about distinct allosteric changes that alter the conformational equilibrium of full-length BTK. Additionally, we provide an explanation for the resistance mutation bias observed in CLL patients treated with different BTKi and characterize the mechanism of action of two common resistance mutations: BTK T474I and L528W.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Roy J. Carver Department of Biochemistry, Biophysics and Molecular Biology, Iowa State University, Ames, United States.
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, United States.
- The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, College of Life Sciences, University of Leicester, Leicester, United Kingdom.
ORCID-Profile: Raji E Joseph, Thomas E Wales, Sandrine Jayne, John R Engen, Martin J S Dyer, Amy H Andreotti
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- Experimental Cancer Medicine Centre
- Roy J. Carver Charitable Trust
Zitieren
APA
Joseph, R. E., Wales, T. E., Jayne, S., Britton, R. G., Fulton, D. B., Engen, J. R., Dyer, M. J. S., & Andreotti, A. H. (2024). Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia. eLife. https://doi.org/10.7554/elife.95488
Vancouver
Joseph RE, Wales TE, Jayne S, Britton RG, Fulton DB, Engen JR, et al. Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia. eLife. 2024. doi:10.7554/elife.95488
BibTeX
@article{Joseph2024,
author = {Joseph, Raji E and Wales, Thomas E and Jayne, Sandrine and Britton, Robert G and Fulton, D Bruce and Engen, John R and Dyer, Martin J S and Andreotti, Amy H},
title = {Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.95488}
}
EUVIMED